A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients with Severe Eosinophilic Asthma Treated with Benralizumab

Trial Identifier: D3250C00072
Sponsor: AstraZeneca
NCTID:: NCT04159519
Start Date: July 2020
Primary Completion Date: February 2023
Study Completion Date: February 2023
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
French Translation
Italian Translation

Trial Locations

Country Location
DE Berlin, DE, 10969
DE Bonn, DE, 53105
DE Cottbus, DE, 03050
DE Freiburg, DE, 79106
DE Hamburg, DE, 22767
DE Hamburg, DE, 20354
DE Hannover, DE, 30625
DE Jena, DE, 7740
DE Mainz, DE, 55131
DE Marburg, DE, 35043
DE München, DE, 81377
FR Brest Cedex, FR, 29609
FR Dijon Cedex, FR, 21079
FR Le Kremlin-Bicêtre, FR, 94270
FR Lille, FR, 59000
FR Lyon Cedex 04, FR, 69317
FR Pessac, FR, 33600
GB Belfast, GB, BT9 7BL
GB Cambridge, GB, CB2 2QQ
GB London, GB, SE1 9RT
GB Nottingham, GB, NG15 1PB
IT Bergamo, IT, 24127
IT Napoli, IT, 80131
IT Roma, IT, 00168